tiprankstipranks
Advertisement
Advertisement

DE:135A Stock Latest News

Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity
RatingsBuy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity
6d ago
SCYX
Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247
PremiumThe Fly
Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247
28d ago
SCYX
Cero Therapeutics appoints Eric Francois to board of directors
PremiumThe Fly
Cero Therapeutics appoints Eric Francois to board of directors
1M ago
CERO
SCYX
Scynexis announces presentation highlighting data from SCY-247
PremiumThe Fly
Scynexis announces presentation highlighting data from SCY-247
2M ago
SCYX
Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247
PremiumThe Fly
Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247
2M ago
SCYX
Scynexis granted 180-day extension by Nasdaq to regain compliance
PremiumThe FlyScynexis granted 180-day extension by Nasdaq to regain compliance
3M ago
SCYX
Scynexis completes transfer of BREXAFEMME NDA to GSK
Premium
The Fly
Scynexis completes transfer of BREXAFEMME NDA to GSK
4M ago
GSK
SCYX
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
Premium
The Fly
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
4M ago
SCYX
SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating
PremiumRatings
SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating
5M ago
SCYX
SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates
PremiumCompany Announcements
SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates
5M ago
SCYX
Scynexis reports Q3 EPS (17c), consensus (20c)
PremiumThe Fly
Scynexis reports Q3 EPS (17c), consensus (20c)
5M ago
SCYX
SCYX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SCYX Upcoming Earnings Report: What to Expect?
5M ago
SCYX
Scynexis price target lowered to $3 from $4 at Guggenheim
PremiumThe FlyScynexis price target lowered to $3 from $4 at Guggenheim
5M ago
GSK
SCYX
SCYNEXIS: Strategic Advancements and Financial Stability Drive Buy Rating
Premium
Ratings
SCYNEXIS: Strategic Advancements and Financial Stability Drive Buy Rating
5M ago
SCYX
SCYNEXIS and GSK Amend License Agreement
Premium
Company Announcements
SCYNEXIS and GSK Amend License Agreement
5M ago
8K
SCYX
Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study
PremiumThe Fly
Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study
5M ago
SCYX
Buy Rating on SCYNEXIS: Promising Potential of SCY-247 Amid Market Volatility
PremiumRatings
Buy Rating on SCYNEXIS: Promising Potential of SCY-247 Amid Market Volatility
6M ago
SCYX
Scynexis announces results from Phase 1 SAD/MAD study of SCY-247
PremiumThe Fly
Scynexis announces results from Phase 1 SAD/MAD study of SCY-247
6M ago
SCYX
Promising Potential of SCY-247: A Game-Changer in Antifungal Treatment
PremiumRatings
Promising Potential of SCY-247: A Game-Changer in Antifungal Treatment
7M ago
SCYX
Scynexis announces presentations highlighting data on SCY-247
PremiumThe FlyScynexis announces presentations highlighting data on SCY-247
7M ago
SCYX
Optimistic Outlook on SCYNEXIS: Strategic Developments and Financial Health Drive Buy Rating
Premium
Ratings
Optimistic Outlook on SCYNEXIS: Strategic Developments and Financial Health Drive Buy Rating
7M ago
SCYX
SCYNEXIS Reports Improved Financials Amidst Strategic Developments
Premium
Company Announcements
SCYNEXIS Reports Improved Financials Amidst Strategic Developments
7M ago
SCYX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >